ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia Board of Directors Appoints Mark R. Straley as New CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announced the appointment of veteran diagnostics industry leader Mark R. Straley as Chief Executive Officer. He succeeds Read More
NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to Predict Prognosis
Respected Panel Cites RASTER, the Only Published Prospective Outcome Data of Its Kind, Which Demonstrates MammaPrint’s Ability to Identify Those Patients Who May Safely Forego Chemotherapy IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a Read More
Agendia Announces Recommendation of MammaPrint in Germany’s AGO Guidelines, at St. Gallen International Breast Cancer Conference
Company Also Highlights FDA Clearance of MammaPrint in FFPE IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, announced at the St. Gallen International Read More
Agendia’s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference
Results of the NBRST Trial Using Agendia’s BluePrint 80-Gene Molecular Subtyping Assay Presented IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, said new Read More